Zhan-Guo Gao

发表

Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists.

David Rodríguez, Jens Carlsson, Saibal Chakraborty, 2016, ACS chemical biology.

Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.

Sang Kook Lee, Kenneth A Jacobson, K. Jacobson, 2009, Bioorganic & medicinal chemistry.

Structure-Based Discovery of A2A Adenosine Receptor Ligands

Brian K. Shoichet, John J. Irwin, Jens Carlsson, 2010, Journal of medicinal chemistry.

Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.

Francesca Deflorian, Kenneth A Jacobson, K. Jacobson, 2012, Journal of medicinal chemistry.

Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.

Carl R. Johnson, Dov Barak, Kenneth A Jacobson, 2002, Journal of medicinal chemistry.

Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

Johannes Brussee, Kenneth A Jacobson, Kai Ye, 2006, Journal of medicinal chemistry.

Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.

Kenneth A Jacobson, K. Jacobson, Zhang-Guo Gao, 2006, Journal of molecular graphics & modelling.

Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

Kenneth A Jacobson, Zhan-Guo Gao, Hea Ok Kim, 2006, Bioorganic & medicinal chemistry letters.

Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.

Kenneth A Jacobson, Kai Ye, K. Jacobson, 2011, Biochemical pharmacology.

Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor.

Kenneth A Jacobson, K. Jacobson, Zhang-Guo Gao, 2003, Molecular pharmacology.

Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.

Sang Kook Lee, Kenneth A Jacobson, Zhan-Guo Gao, 2008, Journal of medicinal chemistry.

Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.

Fei Xu, Francesca Deflorian, Vsevolod Katritch, 2012, Journal of medicinal chemistry.

Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.

Silvia Paoletta, Steven M. Moss, Kenneth A Jacobson, 2013, Journal of medicinal chemistry.

Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.

Kenneth A Jacobson, K. Jacobson, Zhang-Guo Gao, 2004, Bioorganic & medicinal chemistry.

Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.

T Kendall Harden, Stefano Costanzi, Piet Herdewijn, 2004, Bioorganic & medicinal chemistry.

Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.

Adriaan P IJzerman, Kenneth A Jacobson, K. Jacobson, 2002, Molecular pharmacology.

Progress in the pursuit of therapeutic adenosine receptor antagonists

Giampiero Spalluto, Kenneth A Jacobson, S. Moro, 2006, Medicinal research reviews.

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Adriaan P IJzerman, Kenneth A Jacobson, Kai Ye, 2009, BMC pharmacology.

Allosteric modulation of the adenosine family of receptors.

Kenneth A Jacobson, K. Jacobson, A. IJzerman, 2005, Mini reviews in medicinal chemistry.

Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists

Gangadhar J Sanjayan, Kenneth A Jacobson, K. Jacobson, 2010, Journal of nanobiotechnology.

Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor.

Silvia Paoletta, Kenneth A Jacobson, Zhan-Guo Gao, 2014, Bioorganic & medicinal chemistry letters.

Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists.

Silvia Paoletta, Kenneth A Jacobson, K. Jacobson, 2015, MedChemComm.

Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists.

Jens Carlsson, Kenneth A Jacobson, K. Jacobson, 2012, ACS medicinal chemistry letters.

Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists

Peter Kolb, Andrej Sali, Kenneth A. Jacobson, 2012, PloS one.

Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.

Kenneth A Jacobson, K. Jacobson, Philippe van Rompaey, 2003, Journal of medicinal chemistry.

Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.

Ruben Abagyan, Fei Xu, Francesca Deflorian, 2012, Journal of medicinal chemistry.